Last reviewed · How we verify
SHR-9839
At a glance
| Generic name | SHR-9839 |
|---|---|
| Sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors (PHASE1, PHASE2)
- A Phase II Clinical Study of HRS-7058 in Combination With Antitumor Drugs in Patients With Advanced Malignant Tumour (PHASE2)
- A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors (PHASE1, PHASE2)
- A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (PHASE1, PHASE2)
- The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors (PHASE1)
- A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC (PHASE1, PHASE2)
- A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR-9839 CI brief — competitive landscape report
- SHR-9839 updates RSS · CI watch RSS
- Shanghai Hengrui Pharmaceutical Co., Ltd. portfolio CI